PropThink: TH-302 Development: In the Shadow of the Competition
By Jake King
After declines in the first half of the week, shares of Threshold Pharmaceuticals (NASDAQ:THLD) rebounded on Thursday morning following an update on the company's ongoing Phase 2 trial of TH-302 (403 Trial) in soft tissue sarcoma. The drug in combination with doxorubicin demonstrated a median progression free survival (PFS) of 6.7 months, a median overall survival (OS) of 21.5 months, and an acceptable safety profile. In a single-arm component of the study (roughly half of the total patient population) patients continued treatment with TH-302 as a single agent following the doxorubicin combination treatment; median PFS was 3.7 months, and median OS was 18.0 months in the maintenance extension. The Phase 2 supports the ongoing Phase 3 '406 Trial', in which TH-302 plus doxorubicin is being compared to doxorubicin alone as a first-line soft tissue sarcoma treatment; interim data is expected in 1H13. That trial is being carried out under a Special Protocol Assessment with the FDA.
Threshold, however, bears the brunt of upcoming trial results from multiple competitors. Continue reading here.
Click here to see the full article at PropThink.com.
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued. We offer daily market coverage, weekly feature stories, and a newsletter to investors who subscribe on PropThink.com. To learn more, follow us on Twitter or visit us at http://www.propthink.com.
You should assume that as of the publication date of any report or letter, PropThink, LLC and persons or entities with whom it has relation ships (collectively referred to as "PropThink") has a position in all stocks (and/or options of the stock) covered herein that is consistent with the position set forth in our research report. Following publication of any report or letter, PropThink intends to continue transacting in the securities covered herein, and we may be long, short, or neutral at any time hereafter regardless of our initial recommendation. To the best of our knowledge and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and not from company insiders or persons who have a relationship with company insiders. PropThink was not compensated to publish this article. Our full disclaimer is available at .
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein. Source: PropThink via Thomson Reuters ONE